Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Pharvaris N.V. (NASDAQ:PHVS) has an average consensus recommendation of "Moderate Buy" from five brokerage firms, with four having issued buy ratings.
• The stock currently has an average 1-year target price of $34.00, despite notable variability in price targets from different analysts.
• Pharvaris reported a loss of ($0.94) EPS for the most recent quarter, missing the consensus estimate by $0.07 and is forecasted to post -$2.71 EPS for the current fiscal year.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $34.00.

PHVS has been the subject of a number of recent research reports. Guggenheim initiated coverage on Pharvaris in a report on Wednesday, June 11th. They set a "buy" rating and a $32.00 price objective for the company. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a report on Wednesday, August 13th. Zacks Research raised Pharvaris from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $27.00 target price on shares of Pharvaris in a report on Thursday, June 5th.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in shares of Pharvaris in the second quarter valued at approximately $57,000. JPMorgan Chase & Co. lifted its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Pharvaris in the fourth quarter valued at approximately $152,000. Legal & General Group Plc lifted its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock valued at $203,000 after purchasing an additional 1,695 shares during the last quarter. Finally, California State Teachers Retirement System lifted its stake in Pharvaris by 9.8% in the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company's stock valued at $247,000 after purchasing an additional 1,257 shares during the last quarter.

Pharvaris Stock Performance

PHVS traded up $0.82 during midday trading on Friday, reaching $25.36. 382,299 shares of the company were exchanged, compared to its average volume of 140,898. The company's fifty day moving average price is $22.32 and its 200 day moving average price is $18.34. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -7.55 and a beta of -2.80. Pharvaris has a one year low of $11.51 and a one year high of $26.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07). As a group, sell-side analysts anticipate that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.